about
Suitability of pharmacological treatment in patients with multiple chronic conditionsPrevalence of drug interactions in elderly patients with multimorbidity in primary care.Development of a Trigger Tool to Identify Adverse Drug Events in Elderly Patients With Multimorbidity.Prevalence of drug interactions in hospital healthcare.Biological treatments for moderate-to-severe psoriasis: indirect comparison.Systematic review on the use of anticholinergic scales in poly pathological patients.Novel tool for deprescribing in chronic patients with multimorbidity: List of Evidence-Based Deprescribing for Chronic Patients criteria.Assessment of new drugs in a tertiary hospital using a standardized tool.[Deprescribing: guiding its definition].Structure and procedures of the pharmacy and therapeutic committees in Spanish hospitals.Autorización de usos de medicamentos fuera de indicación en un hospital de tercer nivelAnálisis del proceso de selección de nuevos medicamentos en un hospital terciario. Años 2004–07Decision analysis applied to the selection of angiotensin-converting enzyme inhibitors[Clinical significance of drug interactions][Quality of the antiretrovirals drug interactions database][Indirect comparisons in drug assessment reports on the GENESIS group (SEFH) webpage][Classification and variability of drug assessment reports on the GENESIS group (SEFH) webpage]Variability in activity and results from drug assessments by pharmacy and therapeutics committees in Spanish hospitals[Disability as a barrier to drug adherence in polypathological patients: role of main carer][Spanish presence in BPS accreditation][Quality of interaction database management systems]Selection of tools for reconciliation, compliance and appropriateness of treatment in patients with multiple chronic conditionsDeprescribing in patients with multimorbidity: a necessary process[Evaluation of the appropriateness of pharmacotherapy in patients with high comorbidity]Anticholinergic risk: Use and limitations of anticholinergic scalesDeveloping a list of high-alert medications for patients with chronic diseasesReliability of a questionnaire for pharmacological treatment appropriateness in patients with multiple chronic conditions[Health care models for patients with multiple chronic conditions and the role of the hospital pharmacy/the hospital pharmacist][Indirect comparisons, author response][Comment to the article: « Program of pharmacy care in patients with chronic diseases »][Medication reconciliation on hospital admission in patients with multiple chronic diseases using a standardised methodology][Spanish translation and cross-cultural adaptation of the ARMS-scale for measuring medication adherence in polypathological patients]Association Between Drug Burden Index and Functional and Cognitive Function in Patients with MultimorbidityDevelopment of the Anticholinergic Burden Calculator Web Tool[Effectiveness of an intervention strategy in the biosimilar glargine prescription pattern in primary care]
P50
Q26995411-7D102777-3FF3-4E95-9948-890C8C8C209CQ36290903-72C50F40-8859-4E6B-97A7-C9CA049E4A8CQ36406197-CCFEB57F-B42C-4E9E-AD30-7C247B53DAFFQ38042334-32F635B2-7EDD-4EFF-8845-ABA6E477EAC2Q38084746-4CC2FDA7-6DA4-4F94-8D8A-A40ECAB9A5B6Q38620794-F92C2BF6-9D9F-40DE-9140-1D0FFCDE02A7Q39329851-DBA281C1-052B-456A-B6F2-FB8004DDE21EQ45014906-95C8A12F-6211-4C8F-9AAB-24AF1DE5C683Q50121991-F18C08A3-6F0F-4656-8062-A4B5D3DF7C04Q51151724-9F7519C2-8BF8-4A9B-B56C-66505F9555E4Q58227026-4A0F0888-1C46-4825-8983-2335419D64FAQ58227036-A097EB01-1E32-4C98-BA77-33CBC3FDDCE3Q72649396-675CCB07-C8BF-486C-ABF6-F9EF2AD6DE22Q81500752-F9E2D502-BE23-4C31-B3DC-F7EA44A981AAQ83372125-E70DD9EF-39E6-4872-87B4-EFAA6D9D3AFDQ83728908-C3402A76-BB6D-4D28-ACA4-0C2E6E318A46Q83749650-49BC956D-97AC-4E3B-9F97-50E0B6758EA8Q83878667-12CF372C-AA1B-420A-A877-AE4A132DA14BQ84073345-15DF0DC4-705F-4172-B093-1948113A202FQ84107823-D76CC9E6-AF7D-47AC-BAB8-9D307DFEFAC4Q84478771-01C6F86D-D3BD-4A89-9246-2869F83E507BQ84729503-040EEA56-4C97-45D0-B6AE-A37F8C0E0E81Q85541297-08915B6C-3DA6-47E9-ACA3-34DC58CD2514Q85931466-0250569D-5778-4298-9419-B28F5D3B342EQ86127765-826368E1-8CF9-45F1-B403-DB217387CD9CQ86174298-99A5DA1F-0566-4D0C-828F-3F8B67CD3C6EQ86179217-D2BC85AE-AB14-41A0-8BA7-55F455D2DC60Q86275838-47AC6BD7-B2D5-437E-AD6F-B73B4B8A9FA6Q86275909-018B6A15-E0AA-4530-B9DD-C4BD1403194EQ86276107-5927CDD1-2858-419B-B777-2F092A20F3C9Q86488704-879518B7-ECEC-4B5F-B6E1-3E0CB5856E08Q87788096-F3F59FAF-C48D-4D3F-AB95-51F21F32DA52Q88198788-473F9D64-9ED3-4BC8-9739-025C020D3FCEQ88861202-865092AD-68E4-4AAF-A68F-C9E829517C64Q88964287-1BDF3F16-F8D0-44FA-BBB2-3392E2152592
P50
description
researcher
@en
wetenschapper
@nl
name
B Santos Ramos
@en
B Santos Ramos
@nl
type
label
B Santos Ramos
@en
B Santos Ramos
@nl
prefLabel
B Santos Ramos
@en
B Santos Ramos
@nl
P106
P31
P496
0000-0003-4315-351X